
  
    
      
        Introduction_NNP
        Coronary_NNP heart_NN disease_NN (_( CHD_NNP )_) remains_VBZ the_DT leading_VBG cause_NN of_IN morbidity_NN and_CC mortality_NN in_IN the_DT
        United_NNP States_NNPS and_CC is_VBZ associated_VBN with_IN substantial_JJ economic_JJ cost_NN [_NN 1_CD ]_NN ._. Hyperlipidemia_NNP
        represents_VBZ an_DT important_JJ modifiable_JJ risk_NN factor_NN in_IN the_DT development_NN and_CC progression_NN of_IN CHD_NNP ._.
        Estimates_NNS indicate_VBP that_IN nearly_RB 100_CD million_CD American_JJ adults_NNS have_VBP total_JJ blood_NN cholesterol_NN
        levels_NNS of_IN greater_JJR than_IN 5_CD ._. 17_CD mmol_NN /_NN l_NN (_( 200_CD mg_NN /_NN dl_NN )_) with_IN 40_CD %_NN having_VBG levels_NNS greater_JJR than_IN 6_CD ._. 21_CD
        mmol_NN /_NN l_NN (_( 240_CD mg_NN /_NN dl_NN )_) [_NN 2_CD ]_NN ._. Identification_NNP and_CC treatment_NN of_IN patients_NNS with_IN hyperlipidemia_NN play_VBP
        an_DT essential_JJ role_NN in_IN the_DT primary_JJ and_CC secondary_JJ prevention_NN of_IN CHD_NNP ._.
        Currently_RB ,_, evidence-based_JJ practice_NN guidelines_NNS focus_VBP on_IN low-density_NN lipoprotein_NN
        cholesterol_NN (_( LDL-C_NNP )_) as_IN the_DT primary_JJ target_NN for_IN risk_NN reduction_NN therapy_NN and_CC recommend_VB that_IN the_DT
        intensity_NN and_CC target_NN goals_NNS of_IN LDL-C-lowering_NNP therapy_NN should_MD be_VB adjusted_VBN to_TO individual_JJ
        absolute_JJ risk_NN for_IN CHD_NNP [_NN 3_CD ]_NN ._. Absolute_JJ CHD_NNP risk_NN is_VBZ categorized_VBN as_IN low_JJ ,_, moderate_JJ ,_, or_CC high_RB based_VBN
        on_IN the_DT presence_NN or_CC absence_NN of_IN CHD_NNP ,_, CHD-equivalent_NNP conditions_NNS ,_, and_CC major_JJ risk_NN factors_NNS other_JJ
        than_IN LDL-C_NNP ._. While_IN therapeutic_JJ lifestyle_NN changes_NNS are_VBP integral_JJ to_TO general_JJ risk_NN reduction_NN ,_,
        drug_NN treatment_NN proves_VBZ necessary_JJ for_IN selected_VBN patients_NNS whose_WP$ absolute_JJ risk_NN is_VBZ high_NN and_CC /_NN or_CC
        whose_WP$ LDL-C_NNP is_VBZ inadequately_RB controlled_VBN with_IN lifestyle_NN modifications_NNS alone_RB ._. Among_IN existing_VBG
        drug_NN therapies_NNS ,_, 3_CD -_: hydroxy-_NN 3_CD -_: methyl-glutaryl_JJ coenzyme_NN A_DT reductase_NN inhibitors_NNS ,_, more_RBR commonly_RB
        known_VBN as_IN statins_NNS ,_, provide_VBP a_DT generally_RB well-tolerated_JJ and_CC effective_JJ option_NN for_IN lowering_VBG
        LDL-C_NNP levels_NNS and_CC decreasing_VBG the_DT likelihood_NN of_IN subsequent_JJ CHD_NNP events_NNS [_NN 3_CD ,_, 4_CD ]_NN ._.
        Despite_IN the_DT compelling_JJ evidence_NN of_IN statins_NNS '_POS therapeutic_JJ benefits_NNS ,_, the_DT literature_NN abounds_VBZ
        with_IN documentation_NN of_IN wide_JJ treatment_NN gaps_NNS in_IN clinical_JJ practice_NN [_NN 5_CD –_NN 10_CD ]_NN ._. Available_NNP research_NN ,_,
        however_RB ,_, offers_VBZ only_RB a_DT limited_JJ understanding_NN of_IN how_WRB statin_NN therapy_NN varies_VBZ by_IN CHD_NNP risk_NN ,_,
        particularly_RB for_IN statin-eligible_JJ patients_NNS in_IN the_DT moderate-risk_JJ group_NN ._. Also_RB ,_, national_JJ data_NNS
        are_VBP limited_JJ regarding_VBG recent_JJ changes_NNS in_IN statin_NN use_NN ._.
        Using_VBG serial_NN cross-sectional_JJ data_NNS from_IN 1992_CD through_IN 2002_CD ,_, we_PRP tracked_VBD trends_NNS in_IN statin_NN
        use_NN in_IN the_DT United_NNP States_NNPS during_IN ambulatory_JJ visits_NNS categorized_VBN by_IN CHD_NNP risk_NN ,_, with_IN or_CC without_IN
        a_DT diagnosis_NN of_IN hyperlipidemia_NN ._. In_IN addition_NN ,_, we_PRP analyzed_VBD the_DT independent_JJ associations_NNS of_IN
        patient_NN and_CC physician_NN characteristics_NNS with_IN statin_NN use_NN for_IN insights_NNS as_IN to_TO how_WRB to_TO target_VB
        interventions_NNS to_TO improve_VB statin_NN use_NN ._.
      
      
        Methods_NNP
        
          Data_NNP Sources_NNS
          Annual_JJ data_NNS from_IN 1992_CD through_IN 2002_CD were_VBD obtained_VBN from_IN the_DT National_NNP Ambulatory_NNP Medical_NNP
          Care_NNP Survey_NNP (_( NAMCS_NNP )_) and_CC the_DT outpatient_NN department_NN component_NN of_IN the_DT National_NNP Hospital_NNP
          Ambulatory_NNP Medical_NNP Care_NNP Survey_NNP (_( NHAMCS_NNP )_) ._. The_DT National_NNP Center_NNP for_IN Health_NNP Statistics_NNPS
          provides_VBZ complete_JJ descriptions_NNS of_IN both_DT surveys_NNS and_CC yearly_JJ data_NNS at_IN
          http_NN :_: /_NN /_NN www_NN ._. cdc_NN ._. gov_NN /_NN nchs_NNS /_NN about_IN /_NN major_JJ /_NN ahcd_NN /_NN ahcd_NN 1_CD ._. htm_NN ._. These_DT surveys_NNS ,_, particularly_RB NAMCS_NNP ,_,
          have_VBP been_VBN validated_JJ against_IN other_JJ data_NNS sources_NNS [_NN 11_CD ,_, 12_CD ]_NN ,_, and_CC have_VBP also_RB been_VBN utilized_JJ in_IN
          past_JJ research_NN of_IN cholesterol_NN management_NN [_NN 13_CD ]_NN ._.
          In_IN brief_JJ ,_, NAMCS_NNP captures_NNS health-care_NN services_NNS provided_VBN by_IN office-based_JJ physicians_NNS ,_,
          while_IN NHAMCS_NNP assesses_NNS services_NNS offered_VBN at_IN hospital_NN outpatient_NN departments_NNS ._. Both_DT surveys_NNS
          utilize_VB multistage_NN probability_NN sampling_VBG procedures_NNS ,_, enabling_VBG the_DT generation_NN of_IN nationally_RB
          representative_NN estimates_NNS ._. Between_IN 1992_CD and_CC 2002_CD ,_, annual_JJ participation_NN rates_NNS among_IN
          physicians_NNS selected_VBN for_IN NAMCS_NNP averaged_VBD 70_CD %_NN ,_, while_IN the_DT participation_NN rate_NN in_IN NHAMCS_NNP by_IN
          selected_VBN hospitals_NNS with_IN outpatient_NN departments_NNS was_VBD 90_CD %_NN ._. In_IN our_PRP$ study_NN ,_, we_PRP combined_VBD NAMCS_NNP
          and_CC NHAMCS_NNP data_NNS to_TO obtain_VB a_DT wider_JJR range_NN of_IN outpatient_NN settings_NNS and_CC a_DT broader_JJR
          socioeconomic_JJ spectrum_NN of_IN patients_NNS seeking_VBG ambulatory_JJ care_NN ._.
          Standard_NNP encounter_VB forms_NNS were_VBD completed_VBN for_IN a_DT systematic_JJ random_JJ sample_NN of_IN patient_NN
          visits_NNS during_IN randomly_RB assigned_VBN reporting_VBG periods_NNS ._. Item_NNP nonresponse_NN rates_NNS were_VBD mostly_RB 5_CD %_NN
          or_CC less_JJR in_IN both_DT surveys_NNS for_IN all_DT years_NNS ._. Yearly_JJ encounter_NN forms_NNS varied_VBD slightly_RB between_IN
          NAMCS_NNP and_CC NHAMCS_NNP and_CC were_VBD revised_VBN every_DT two_CD years_NNS ._. Our_PRP$ analysis_NN focused_VBN on_IN domains_NNS of_IN
          data_NNS that_WDT were_VBD consistently_RB collected_VBN in_IN both_DT NAMCS_NNP and_CC NHAMCS_NNP for_IN the_DT time_NN period_NN
          1992_CD –_NN 2002_CD ,_, including_VBG patient_NN demographic_JJ and_CC geography_NN characteristics_NNS ,_, reasons_NNS for_IN visit_NN
          (_( up_IN to_TO three_CD )_) ,_, diagnoses_NNS (_( up_IN to_TO three_CD )_) ,_, new_JJ and_CC continuing_VBG medications_NNS (_( up_IN to_TO five_CD in_IN
          1992_CD –_NN 1994_CD and_CC six_CD in_IN 1995_CD –_NN 2002_CD )_) ,_, and_CC lifestyle_NN counseling_NN services_NNS provided_VBN or_CC ordered_VBN at_IN
          the_DT visit_NN ._.
        
        
          Participants_NNS
          
            CHD_NNP risk_NN categorization_NN
            We_PRP estimated_VBD CHD_NNP risk_NN for_IN adults_NNS aged_VBN 20_CD y_NN and_CC older_JJR based_VBN on_IN risk_NN factor_NN counting_NN ._.
            CHD_NNP risk_NN was_VBD mutually_RB exclusively_RB categorized_VBN as_IN low_JJ (_( 0_CD –_NN 1_CD risk_NN factors_NNS )_) ,_, moderate_JJ (_( 2_CD +_NN
            risk_NN factors_NNS )_) ,_, or_CC high_JJ (_( CHD_NNP ,_, other_JJ atherosclerotic_JJ diseases_NNS ,_, or_CC diabetes_NN )_) ._. The_DT
            moderate-risk_JJ group_NN included_VBD visits_NNS by_IN patients_NNS without_IN CHD_NNP or_CC equivalent_NN but_CC with_IN at_IN
            least_JJS two_CD of_IN the_DT following_VBG risk_NN factors_NNS :_: age_NN (_( for_IN men_NNS ,_, >_NN 45_CD y_NN ;_: for_IN women_NNS ,_, >_NN 55_CD y_NN )_) ,_,
            cigarette_NN smoking_NN ,_, or_CC a_DT physician-reported_JJ diagnosis_NN of_IN hypertension_NN ._. Unfortunately_RB ,_,
            the_DT other_JJ two_CD major_JJ CHD_NNP risk_NN factors—high-density_JJ lipoprotein_NN cholesterol_NN levels_NNS and_CC
            family_NN history_NN of_IN premature_JJ CHD—were_NNP not_RB captured_VBD in_IN either_DT data_NNS source_NN ._. Also_RB ,_, neither_DT
            data_NNS source_NN provided_VBD actual_JJ cholesterol_NN measurements_NNS ._. Disease_NN conditions_NNS were_VBD
            identified_VBN by_IN International_NNP Classification_NNP of_IN Disease_NNP (_( ICD-_NNP 9_CD )_) codes_NNS ,_, as_RB well_RB as_IN by_IN the_DT
            appropriate_JJ reason-for-visit_JJ codes_NNS that_WDT are_VBP specific_JJ to_TO NAMCS_NNP and_CC NHAMCS_NNP ._. For_IN instance_NN ,_,
            we_PRP identified_VBD patients_NNS as_IN having_VBG hyperlipidemia_NN if_IN their_PRP$ encounter_NN forms_NNS contained_VBD an_DT
            International_NNP Classification_NNP of_IN Disease_NNP code_NN within_IN 272_CD ._. 0_CD –_NN 272_CD ._. 4_LS ._. For_IN the_DT sake_NN of_IN this_DT
            study_NN ,_, patients_NNS whose_WP$ encounter_VB forms_NNS did_VBD not_RB indicate_VB the_DT presence_NN of_IN a_DT condition_NN were_VBD
            assumed_VBN to_TO not_RB have_VB that_DT condition_NN ._.
          
          
            Patient_NNP visit_NN characteristics_NNS ._.
            Nonclincal_NNP characteristics_NNS included_VBD patient_NN age_NN ,_, gender_NN ,_, race_NN /_NN ethnicity_NN ,_, medical_JJ
            insurance_NN ,_, visit_NN status_NN ,_, United_NNP States_NNPS census_NN region_NN ,_, metropolitan_JJ area_NN status_NN ,_,
            physician_NN specialty_NN ,_, and_CC practice_NN setting_NN ._. Medical_JJ insurance_NN was_VBD classified_VBN as_IN
            private_JJ /_NN commercial_JJ ,_, public_JJ (_( i_NNP ._. e_SYM ._. ,_, Medicare_NNP and_CC Medicaid_NNP )_) ,_, or_CC other_JJ (_( e_SYM ._. g_SYM ._. ,_, workers_NNS '_POS
            compensation_NN or_CC self-pay_JJ )_) ._. Visit_NNP status_NN distinguished_VBD first-time_JJ visits_NNS from_IN return_NN
            visits_NNS to_TO a_DT practice_NN ._. Physician_NN specialty_NN was_VBD available_JJ only_RB from_IN NAMCS_NNP ,_, which_WDT
            contributed_VBD more_JJR than_IN 90_CD %_NN of_IN the_DT total_JJ visits_NNS for_IN each_DT of_IN the_DT study_NN years_NNS ._. We_PRP
            categorized_VBN physician_NN specialties_NNS as_IN cardiology_NN ,_, internal_JJ medicine_NN ,_, general_NN and_CC family_NN
            practice_NN ,_, or_CC other_JJ ._.
          
          
            Measures_NNS
            Of_IN primary_JJ interest_NN were_VBD the_DT rate_NN of_IN statin_NN use_NN relative_JJ to_TO CHD_NNP risk_NN and_CC the_DT
            relationship_NN of_IN statin_NN use_NN to_TO patient_NN visit_NN characteristics_NNS ._. The_DT rate_NN of_IN statin_NN use_NN was_VBD
            calculated_VBN as_IN the_DT proportion_NN of_IN patient_NN visits_NNS where_WRB a_DT statin_NN was_VBD reported_VBN (_( i_NNP ._. e_SYM ._. ,_,
            atorvastatin_NN ,_, lovastatin_NN ,_, pravastatin_NN ,_, simvastatin_NN ,_, or_CC fluvastatin_NN )_) ._. Before_IN its_PRP$ removal_NN
            from_IN the_DT market_NN in_IN 2001_CD ,_, cerivastatin_NN was_VBD used_VBN scarcely_RB (_( <_NN 2_CD %_NN among_IN visits_NNS by_IN
            patients_NNS with_IN hyperlipidemia_NN )_) and_CC therefore_RB is_VBZ not_RB reported_VBN in_IN this_DT study_NN ._. Measuring_NN
            the_DT rate_NN of_IN statin_NN use_NN by_IN CHD_NNP risk_NN category_NN provided_VBD a_DT relative_JJ indicator_NN of_IN
            appropriate_JJ prescribing_VBG patterns_NNS ,_, that_WDT is_VBZ ,_, the_DT prevalence_NN of_IN statin_NN use_NN should_MD be_VB
            highest_JJS among_IN high-risk_JJ patients_NNS ,_, for_IN whom_WP secondary_JJ prevention_NN is_VBZ a_DT priority_NN ._.
            Variations_NNP of_IN statin_NN use_NN by_IN patient_NN visit_NN characteristics_NNS ,_, if_IN detected_VBD ,_, would_MD reflect_VB a_DT
            lack_NN of_IN equity_NN in_IN processes_NNS of_IN care_NN in_IN that_DT uniform_NN practices_NNS are_VBP expected_VBN unless_IN
            evidence-based_JJ guidelines_NNS recommend_VBP otherwise_RB ._.
          
          
            Analyses_NNS
            Statistical_NNP analyses_NNS were_VBD performed_VBN using_VBG SAS_NNP for_IN Windows_NNP software_NN (_( SAS_NNP Institute_NNP ,_,
            Cary_NNP ,_, North_NNP Carolina_NNP ,_, United_NNP States_NNPS )_) and_CC SAS-callable_NNP SUDAAN_NNP software_NN (_( RTI_NNP ,_, Research_NNP
            Triangle_NNP Park_NNP ,_, North_NNP Carolina_NNP ,_, United_NNP States_NNPS )_) to_TO account_VB for_IN sampling_VBG weights_NNS and_CC the_DT
            complex_JJ survey_NN design_NN ._. The_DT unit_NN of_IN analysis_NN is_VBZ the_DT patient_NN visit_NN ._. We_PRP report_VBP national_JJ
            annual_JJ means_NNS of_IN the_DT rate_NN of_IN statin_NN use_NN by_IN CHD_NNP risk_NN category_NN and_CC corresponding_JJ 99_CD %_NN
            confidence_NN intervals_NNS for_IN the_DT years_NNS 1992_CD through_IN 2002_CD ._. χ_NN
            2_CD tests_NNS examined_VBD the_DT association_NN of_IN statin_NN use_NN with_IN individual_JJ
            patient_NN visit_NN characteristics_NNS for_IN combined_VBN 1995_CD –_NN 2002_CD NAMCS_NNP and_CC NHAMCS_NNP data_NNS ._. The_DT
            independent_JJ effect_NN of_IN each_DT patient_NN visit_NN characteristic_JJ on_IN statin_NN use_NN after_IN controlling_VBG
            for_IN all_DT other_JJ characteristics_NNS was_VBD assessed_VBN with_IN multivariate_NN logistic_JJ regression_NN ._.
          
        
      
      
        Results_NNS
        In_IN 2002_CD ,_, visits_NNS by_IN patients_NNS at_IN moderate_JJ or_CC high_JJ risk_NN involved_VBN higher_JJR proportions_NNS of_IN
        older_JJR patients_NNS (_( mean_VB age_NN 65_CD y_NN )_) than_IN low-risk_JJ patient_NN visits_NNS (_( mean_VB age_NN 51_CD y_NN )_) ,_, and_CC
        consequently_RB were_VBD more_RBR likely_JJ to_TO be_VB covered_VBN by_IN public_JJ insurance_NN ,_, particularly_RB Medicaid_NNP
        (_( Table_NNP 1_LS )_) ._. Moderate-_NNP and_CC high-risk_JJ patient_NN visits_NNS also_RB were_VBD made_VBN up_RP of_IN more_JJR men_NNS and_CC return_NN
        patients_NNS ._. In_IN addition_NN ,_, a_DT greater_JJR percentage_NN of_IN high-risk_JJ patient_NN visits_NNS (_( 11_CD %_NN )_) were_VBD seen_VBN by_IN
        cardiologists_NNS than_IN patient_NN visits_NNS at_IN low_JJ and_CC moderate_JJ risk_NN (_( 2_CD %_NN and_CC 4_CD %_NN ,_, respectively_RB )_) ._.
        Internists_NNP and_CC general_NN and_CC family_NN practitioners_NNS played_VBD a_DT dominant_JJ role_NN in_IN the_DT care_NN of_IN
        moderate-_NN and_CC high-risk_JJ patients_NNS ,_, accounting_NN for_IN 69_CD %_NN of_IN visits_NNS by_IN moderate-risk_JJ patients_NNS
        and_CC 58_CD %_NN of_IN visits_NNS by_IN high-risk_JJ patients_NNS ._. Distributions_NNP by_IN race_NN /_NN ethnicity_NN ,_, geographic_JJ
        region_NN ,_, residence_NN area_NN ,_, and_CC practice_NN setting_VBG did_VBD not_RB differ_VB by_IN CHD_NNP risk_NN ._. Overall_RB ,_, the_DT
        majority_NN of_IN patient_NN visits_NNS were_VBD return_NN visits_NNS to_TO office-based_JJ physicians_NNS made_VBN by_IN
        non-_NN Hispanic_JJ whites_NNS and_CC residents_NNS living_VBG within_IN metropolitan_JJ statistic_NN areas_NNS ._. Patient_NNP
        visits_NNS were_VBD distributed_VBN similarly_RB across_IN the_DT four_CD geographic_JJ regions_NNS ,_, with_IN a_DT slightly_RB
        higher_JJR proportion_NN from_IN the_DT southern_JJ region_NN ._.
        Throughout_IN the_DT study_NN period_NN ,_, statins_NNS were_VBD primarily_RB used_VBN among_IN patients_NNS whose_WP$ visit_NN
        involved_VBN reported_VBD hyperlipidemia_NN ,_, representing_VBG 97_CD %_NN of_IN all_DT statin_NN use_NN in_IN 1992_CD and_CC 91_CD %_NN in_IN
        2002_CD ._. Statin_NNP use_NN increased_VBD nearly_RB 5_CD -_: fold_VB from_IN 9_CD %_NN (_( 99_CD %_NN confidence_NN interval_NN :_: 7_CD %_NN –_NN 12_CD %_NN )_) of_IN all_DT
        visits_NNS with_IN reported_JJ hyperlipidemia_NN in_IN 1992_CD to_TO 49_CD %_NN (_( 42_CD %_NN –_NN 55_CD %_NN )_) in_IN 2000_CD ,_, but_CC then_RB declined_VBD to_TO
        36_CD %_NN (_( 31_CD %_NN –_NN 42_CD %_NN )_) in_IN 2002_CD (_( Figure_NN 1_LS )_) ._. Of_IN note_NN ,_, however_RB ,_, the_DT annual_JJ rate_NN of_IN increase_NN in_IN
        frequency_NN of_IN patient_NN visits_NNS with_IN reported_JJ hyperlipidemia_NN was_VBD 34_CD %_NN in_IN 2001_CD and_CC 21_CD %_NN in_IN 2002_CD ,_,
        while_IN it_PRP averaged_VBD only_RB 12_CD %_NN through_IN 2000_CD ._. The_DT dominance_NN of_IN statins_NNS as_IN lipid-lowering_JJ agents_NNS
        grew_VBD markedly_RB from_IN 47_CD %_NN of_IN all_DT lipid-lowering_JJ medications_NNS in_IN 1992_CD to_TO 87_CD %_NN in_IN 2002_CD (_( Figure_NN 1_LS )_) ._.
        Among_IN available_JJ statins_NNS ,_, lovastatin_NN remained_VBD the_DT therapeutic_JJ choice_NN through_IN 1996_CD ,_, after_IN
        which_WDT it_PRP was_VBD surpassed_VBN by_IN other_JJ statins_NNS ,_, particularly_RB simvastatin_NN and_CC then_RB atorvastatin_NN
        (_( Figure_NN 2_LS )_) ._. Atorvastatin_NNP constituted_VBD 51_CD %_NN (_( 46_CD %_NN –_NN 56_CD %_NN )_) and_CC simvastatin_NN 32_CD %_NN (_( 27_CD %_NN –_NN 36_CD %_NN )_) of_IN all_DT
        statin_NN use_NN in_IN 2002_CD ._.
        As_IN expected_VBN ,_, high_JJ CHD_NNP risk_NN patient_NN visits_NNS resulted_VBD in_IN greater_JJR statin_NN use_NN ,_, and_CC the_DT
        divergence_NN in_IN statin_NN use_NN among_IN the_DT three_CD risk_NN categories_NNS has_VBZ grown_VBN in_IN recent_JJ years_NNS ._.
        Absolute_JJ increases_NNS in_IN the_DT rate_NN of_IN statin_NN use_NN were_VBD greatest_JJS for_IN high-risk_JJ patient_NN visits_NNS
        with_IN or_CC without_IN reported_JJ hyperlipidemia—a_NN 15_CD percentage-point_JJ increase_NN from_IN 4_CD %_NN of_IN all_DT
        visits_NNS in_IN 1992_CD to_TO 19_CD %_NN in_IN 2002_CD —_NN followed_VBN by_IN a_DT nine_CD percentage-point_JJ increase_NN (_( 2_CD %_NN to_TO 11_CD %_NN )_) for_IN
        moderate-risk_JJ patient_NN visits_NNS and_CC a_DT 2_CD ._. 5_CD percentage-point_JJ increase_NN (_( 0_CD ._. 3_LS %_NN to_TO 2_CD ._. 8_CD %_NN )_) for_IN
        low-risk_JJ patient_NN visits_NNS (_( Figure_NN 3_LS )_) ._. Statin_NNP use_NN in_IN the_DT moderate-risk_JJ group_NN peaked_VBD at_IN 14_CD %_NN
        (_( 10_CD %_NN –_NN 17_CD %_NN )_) in_IN 1999_CD ._. Similarly_RB ,_, the_DT rate_NN of_IN statin_NN use_NN in_IN the_DT high-risk_JJ group_NN declined_VBD
        slightly_RB from_IN 2001_CD to_TO 2002_CD ._.
        Among_IN patient_NN visits_NNS with_IN reported_JJ hyperlipidemia_NN ,_, statins_NNS were_VBD used_VBN in_IN 14_CD %_NN (_( 8_CD %_NN –_NN 19_CD %_NN )_) of_IN
        high-risk_JJ visits_NNS and_CC 9_CD %_NN (_( 5_CD %_NN –_NN 14_CD %_NN )_) of_IN moderate-risk_JJ visits_NNS in_IN 1992_CD ._. The_DT high-risk_JJ group_NN 's_POS
        statin_NN use_NN rate_NN rose_VBD to_TO 60_CD %_NN (_( 49_CD %_NN –_NN 71_CD %_NN )_) in_IN 2000_CD and_CC was_VBD 50_CD %_NN (_( 40_CD %_NN –_NN 61_CD %_NN )_) in_IN 2002_CD ._. Likewise_RB ,_, the_DT
        rate_NN in_IN the_DT moderate-risk_JJ group_NN climbed_VBD to_TO 56_CD %_NN (_( 42_CD %_NN –_NN 70_CD %_NN )_) in_IN 1999_CD and_CC stabilized_VBN at_IN 44_CD %_NN
        (_( 32_CD %_NN –_NN 57_CD %_NN )_) in_IN 2002_CD ._. In_IN addition_NN ,_, lifestyle_NN counseling_NN (_( i_NNP ._. e_SYM ._. ,_, regarding_VBG diet_NN ,_, exercise_NN ,_, or_CC
        smoking_NN cessation_NN )_) occurred_VBD in_IN only_RB 43_CD %_NN (_( 32_CD %_NN –_NN 53_CD %_NN )_) of_IN new_JJ and_CC general_JJ medical_JJ examination_NN
        visits_NNS in_IN 2002_CD for_IN patients_NNS who_WP had_VBD moderate_JJ CHD_NNP risk_NN and_CC were_VBD diagnosed_VBN with_IN
        hyperlipidemia_NN ._. Improvements_NNP over_IN time_NN in_IN counseling_NN rates_NNS were_VBD minimal_JJ ._.
        The_DT increase_NN in_IN statin_NN use_NN with_IN CHD_NNP risk_NN and_CC with_IN the_DT year_NN of_IN study_NN persisted_VBD after_IN
        controlling_VBG for_IN physician-reported_JJ hyperlipidemia_NN ,_, number_NN of_IN medications_NNS ,_, and_CC nonclinical_JJ
        patient_NN visit_NN characteristics_NNS (_( Table_NNP 2_LS )_) ._. Moderate-_NNP to_TO high-risk_JJ patient_NN visits_NNS had_VBD a_DT 1_CD ._. 2_CD -_:
        to_TO 2_CD ._. 5_CD -_: fold_VB greater_JJR likelihood_NN of_IN taking_VBG a_DT statin_NN relative_JJ to_TO visits_NNS by_IN patients_NNS at_IN low_JJ
        risk_NN ._. Statin_NNP use_NN was_VBD approximately_RB three_CD times_NNS as_IN likely_JJ in_IN 2001_CD and_CC 2002_CD as_IN in_IN 1995_CD and_CC
        1996_CD ._. Additionally_RB ,_, lower_JJR statin_NN use_NN was_VBD independently_RB associated_VBN with_IN younger_JJR patient_NN age_NN ,_,
        female_JJ gender_NN ,_, African_NNP American_JJ background_NN (_( versus_CC non-_NN Hispanic_JJ white_JJ )_) ,_, non-cardiologist_JJ
        care_NN ,_, and_CC fewer_RBR total_NN reported_VBD medications_NNS ._.
      
      
        Discussion_NNP
        Despite_IN significant_JJ increases_NNS from_IN 1992_CD to_TO 2002_CD in_IN use_NN of_IN statins_NNS associated_VBN with_IN
        hyperlipidemic_JJ patient_NN visits_NNS ,_, the_DT magnitude_NN of_IN increases_NNS is_VBZ smaller_JJR than_IN expected_VBN and_CC the_DT
        rate_NN of_IN use_NN remains_VBZ suboptimal_NN according_VBG to_TO the_DT best_JJS available_JJ evidence_NN ._. The_DT underuse_NN of_IN
        statins_NNS is_VBZ most_RBS prominent_JJ among_IN visits_NNS by_IN patients_NNS at_IN high_JJ or_CC moderate_JJ risk_NN of_IN CHD_NNP who_WP do_VBP
        not_RB have_VB a_DT physician-noted_JJ diagnosis_NN of_IN hyperlipidemia_NN but_CC may_MD nonetheless_RB be_VB eligible_JJ for_IN
        lipid-lowering_JJ drug_NN therapy_NN ._. Previous_JJ research_NN reports_NNS that_IN physicians_NNS are_VBP more_RBR likely_JJ to_TO
        diagnose_NN hyperlipidemia_NN if_IN laboratory_NN reports_NNS show_VBP abnormal_JJ lipid_NN levels_NNS [_NN 14_CD ]_NN ._. However_RB ,_, the_DT
        normal_JJ ranges_NNS of_IN lipid_NN levels_NNS on_IN many_JJ laboratory_NN reports_NNS do_VBP not_RB take_VB into_IN account_NN
        individual_JJ patients_NNS '_POS absolute_JJ risk_NN ._.
        When_WRB evaluating_VBG statin_NN use_NN across_IN different_JJ CHD_NNP risk_NN categories_NNS ,_, the_DT observed_VBD trends_NNS
        raise_VBP several_JJ issues_NNS ._. Both_DT the_DT rate_NN of_IN statin_NN use_NN and_CC the_DT absolute_JJ increases_NNS in_IN the_DT rate_NN
        over_IN time_NN were_VBD positively_RB associated_VBN with_IN the_DT level_NN of_IN CHD_NNP risk_NN ,_, which_WDT appropriately_RB
        conforms_VBZ to_TO the_DT notion_NN of_IN risk_NN stratification_NN ._. The_DT associations_NNS persisted_VBD after_IN adjusting_VBG
        for_IN potentially_RB confounding_VBG factors_NNS such_JJ as_IN a_DT hyperlipidemia_NN diagnosis_NN and_CC nonclinical_JJ
        patient_NN visit_NN characteristics_NNS ._. Even_RB so_RB ,_, in_IN 2002_CD ,_, one_CD year_NN after_IN the_DT publication_NN of_IN Adult_NNP
        Treatment_NNP Panel_NNP III_NNP [_NN 3_CD ]_NN ,_, statins_NNS were_VBD reportedly_RB used_VBN in_IN only_RB 19_CD %_NN of_IN patient_NN visits_NNS with_IN
        established_VBN CHD_NNP or_CC its_PRP$ equivalents_NNS ,_, and_CC the_DT average_JJ rate_NN was_VBD no_RB higher_JJR than_IN 50_CD %_NN among_IN
        high-risk_JJ visits_NNS where_WRB a_DT diagnosis_NN of_IN hyperlipidemia_NN also_RB was_VBD noted_VBN ._. These_DT data_NNS suggest_VBP a_DT
        dramatic_JJ treatment_NN gap_NN ._. Another_DT analysis_NN based_VBN on_IN national_JJ data_NNS estimated_VBD that_IN 72_CD %_NN of_IN
        Americans_NNPS with_IN existing_VBG CHD_NNP would_MD benefit_VB from_IN drug_NN therapy_NN to_TO achieve_VB the_DT target_NN LDL-C_NNP
        goal_NN of_IN 2_CD ._. 59_CD mmol_NN /_NN l_NN (_( 100_CD mg_NN /_NN dl_NN )_) or_CC less_JJR ,_, assuming_VBG a_DT 10_CD %_NN LDL-C_NNP reduction_NN with_IN diet_NN [_NN 15_CD ]_NN ._.
        However_RB ,_, only_RB 11_CD %_NN of_IN those_DT eligible_JJ individuals_NNS received_VBD lipid-lowering_JJ drug_NN therapy_NN ,_,
        suggesting_VBG a_DT gap_NN of_IN 89_CD %_NN [_NN 15_CD ]_NN ._. These_DT obvious_JJ treatment_NN gaps_NNS are_VBP disconcerting_VBG ,_, especially_RB in_IN
        light_NN of_IN the_DT recent_JJ Adult_NNP Treatment_NNP Panel_NNP III_NNP update_VB [_NN 16_CD ]_NN that_WDT supports_VBZ more_RBR intensive_JJ
        lipid-lowering_JJ drug_NN therapy_NN for_IN patients_NNS at_IN high_JJ and_CC moderately_RB high_JJ risk_NN for_IN a_DT heart_NN
        attack_NN ._. Barriers_NNP to_TO adequate_JJ treatment_NN of_IN high-risk_JJ patients_NNS may_MD stem_VB from_IN the_DT patient_NN
        (_( e_SYM ._. g_SYM ._. ,_, lack_NN of_IN drug_NN adherence_NN ,_, concern_NN about_IN adverse_JJ effects_NNS ,_, inadequate_JJ knowledge_NN of_IN their_PRP$
        hyperlipidemia_NN ,_, and_CC drug_NN cost_NN )_) ,_, the_DT physician_NN (_( e_SYM ._. g_SYM ._. ,_, lack_NN of_IN guideline_NN awareness_NN ,_, failure_NN
        to_TO measure_VB lipid_NN levels_NNS ,_, and_CC overestimation_NN of_IN actual_JJ treatment_NN )_) ,_, and_CC the_DT health-care_NN
        system_NN (_( e_SYM ._. g_SYM ._. ,_, lack_NN of_IN monitoring_VBG and_CC follow-up_JJ and_CC emphasis_NN on_IN acute_JJ medical_JJ problems_NNS )_)
        [_NN 10_CD ]_NN ._. If_IN the_DT current_JJ practice_NN continues_VBZ ,_, the_DT observed_VBN treatment_NN gaps_NNS are_VBP expected_VBN to_TO
        persist_VB or_CC even_RB widen_VB ._.
        While_IN statins_NNS deliver_VBP the_DT greatest_JJS benefits_NNS when_WRB used_VBN for_IN secondary_JJ prevention_NN ,_, evidence_NN
        continues_VBZ to_TO accumulate_VBP that_WDT suggests_VBZ an_DT important_JJ role_NN of_IN statins_NNS in_IN the_DT primary_JJ
        prevention_NN of_IN cardiovascular_JJ events_NNS ,_, particularly_RB for_IN patients_NNS at_IN increased_VBN risk_NN [_NN 6_CD ,_, 17_CD ]_NN ._.
        Our_PRP$ data_NNS show_VBP an_DT increase_NN in_IN statin_NN use_NN from_IN 2_CD %_NN of_IN moderate-risk_JJ patient_NN visits_NNS in_IN 1992_CD to_TO
        14_CD %_NN in_IN 1999_CD ,_, but_CC without_IN continued_JJ growth_NN subsequently_RB ._. Optimal_NNP proportions_NNS could_MD not_RB be_VB
        determined_VBN because_IN of_IN the_DT lack_NN of_IN detailed_JJ clinical_JJ data_NNS ._. Nonetheless_RB ,_, National_NNP Health_NNP and_CC
        Nutrition_NNP Examination_NNP Survey_NNP III_NNP data_NNS showed_VBD that_IN 60_CD %_NN of_IN 38_CD ._. 5_LS million_CD adult_NN Americans_NNPS
        without_IN CHD_NNP who_WP had_VBD two_CD or_CC more_JJR risk_NN factors_NNS had_VBD an_DT LDL-C_NNP level_NN above_IN the_DT recommended_VBN 3_CD ._. 36_CD
        mmol_NN /_NN l_NN (_( 130_CD mg_NN /_NN dl_NN )_) and_CC that_IN 45_CD %_NN would_MD remain_VB eligible_JJ for_IN drug_NN therapy_NN even_RB after_IN a_DT 10_CD %_NN
        decrease_NN in_IN LDL-C_NNP with_IN diet_NN [_NN 15_CD ]_NN ._. In_IN addition_NN ,_, Fedder_NNP and_CC colleagues_NNS found_VBD a_DT doubling_VBG
        effect_NN in_IN the_DT number_NN eligible_JJ for_IN primary_JJ prevention_NN drug_NN therapy_NN by_IN switching_VBG to_TO
        Framingham_NNP risk_NN scoring_VBG [_NN 18_CD ]_NN ._. Other_JJ researchers_NNS have_VBP reported_VBN that_IN the_DT proportions_NNS of_IN
        treatment-eligible_JJ primary_JJ prevention_NN patients_NNS who_WP received_VBD no_DT drug_NN therapy_NN reached_VBN as_RB high_JJ
        as_IN 97_CD %_NN [_NN 5_CD ,_, 19_CD ]_NN ._. In_IN our_PRP$ study_NN ,_, statin_NN use_NN was_VBD reported_VBN in_IN only_RB 44_CD %_NN of_IN moderate-risk_JJ patient_NN
        visits_NNS for_IN which_WDT a_DT diagnosis_NN of_IN hyperlipidemia_NN was_VBD noted_VBN ,_, which_WDT is_VBZ surprisingly_RB low_RB given_VBN
        that_IN the_DT entire_JJ group_NN would_MD be_VB expected_VBN to_TO benefit_VB from_IN statin_NN therapy_NN ._. We_PRP also_RB concur_VB with_IN
        other_JJ researchers_NNS who_WP have_VBP discussed_VBN the_DT role_NN that_IN inadequate_JJ lifestyle_NN counseling_NN plays_VBZ in_IN
        the_DT existing_VBG cholesterol_NN treatment_NN gaps_NNS [_NN 10_CD ,_, 13_CD ]_NN ._. Our_PRP$ data_NNS show_VBP that_DT lifestyle_NN counseling_NN
        occurred_VBD during_IN fewer_JJR than_IN 50_CD %_NN of_IN new_JJ and_CC general_JJ medical_JJ examination_NN visits_NNS by_IN
        moderate-risk_JJ patients_NNS ,_, even_RB though_IN these_DT types_NNS of_IN visits_NNS arguably_RB represent_VBP better_JJR
        opportunities_NNS for_IN counseling_NN services_NNS than_IN return_NN ,_, illness-focused_JJ visits_NNS ._.
        It_PRP is_VBZ intriguing_JJ to_TO note_VB that_IN earlier_JJR increases_NNS in_IN statin_NN use_NN were_VBD not_RB sustained_VBN in_IN 2001_CD
        and_CC 2002_CD ._. Studies_NNS using_VBG alternative_JJ data_NNS sources_NNS are_VBP needed_VBN to_TO corroborate_VBP this_DT
        observation_NN ,_, and_CC detailed_JJ market_NN research_NN is_VBZ necessary_JJ for_IN understanding_VBG the_DT underlying_VBG
        causes_NNS of_IN this_DT unexpected_JJ decline_NN in_IN use_NN ._. We_PRP speculate_VBP that_IN the_DT observed_VBN trends_NNS may_MD be_VB
        partially_RB explained_VBN by_IN discordant_JJ rates_NNS of_IN increase_NN in_IN the_DT diagnosis_NN of_IN hyperlipidemia_NN
        versus_CC the_DT prescribing_VBG of_IN statins_NNS ._. Also_RB ,_, NAMCS_NNP and_CC NHAMCS_NNP data_NNS released_VBN after_IN 2002_CD will_MD
        help_VB determine_VB whether_IN the_DT noted_VBN declines_NNS are_VBP due_JJ to_TO random_JJ fluctuations_NNS in_IN data_NNS
        reporting_VBG ._.
        Wide_NNP gaps_NNS between_IN evidence-based_JJ lipid-lowering_JJ therapy_NN and_CC physician_NN practice_NN were_VBD
        reported_VBN in_IN many_JJ other_JJ western_JJ countries_NNS as_RB well_RB ._. For_IN instance_NN ,_, a_DT survey_NN conducted_VBN in_IN nine_CD
        European_JJ countries_NNS found_VBD that_IN only_RB 32_CD %_NN of_IN patients_NNS with_IN confirmed_VBD CHD_NNP received_VBD
        lipid-lowering_JJ medications_NNS [_NN 20_CD ]_NN ._. Likewise_RB ,_, in_IN a_DT population-based_JJ study_NN from_IN the_DT
        Netherlands_NNP ,_, merely_RB 16_CD %_NN of_IN individuals_NNS eligible_JJ for_IN lipid-lowering_JJ drugs_NNS were_VBD actually_RB
        treated_VBN [_NN 7_CD ]_NN ._.
        In_IN spite_NN of_IN being_VBG clearly_RB underused_JJ ,_, statins_NNS increasingly_RB dominate_VBP lipid-lowering_JJ drug_NN
        therapy_NN ,_, accounting_NN for_IN 92_CD %_NN of_IN all_DT lipid-lowering_JJ medications_NNS used_VBN in_IN 2002_CD ,_, which_WDT confirms_VBZ
        the_DT trends_NNS seen_VBN in_IN United_NNP States_NNPS retail_JJ pharmacy_NN dispensing_VBG data_NNS [_NN 2_CD ]_NN ._. Also_RB ,_, in_IN concert_NN with_IN
        other_JJ researchers_NNS [_NN 21_CD ]_NN ,_, we_PRP observed_VBD a_DT shift_NN in_IN the_DT leading_VBG statin_NN prescribed_VBN over_IN time_NN ,_,
        from_IN lovastatin_NN to_TO simvastatin_NN and_CC then_RB to_TO atorvastatin_NN ,_, corresponding_JJ to_TO their_PRP$ market_NN
        entry_NN ._. Atorvastatin_NNP accounted_VBD for_IN over_IN half_NN of_IN all_DT statin_NN use_NN in_IN 2002_CD ._. Even_RB though_IN most_JJS
        statins_NNS share_VBP similar_JJ tolerability_NN ,_, some_DT evidence_NN shows_VBZ that_DT atorvastatin_NN has_VBZ greater_JJR
        dose-specific_JJ potency_NN for_IN lowering_VBG LDL-C_NNP and_CC total_JJ cholesterol_NN [_NN 22_CD ]_NN ._.
        Additionally_RB ,_, our_PRP$ data_NNS add_VBP support_NN to_TO available_JJ literature_NN documenting_VBG inequities_NNS in_IN use_NN
        of_IN statins_NNS for_IN patients_NNS with_IN different_JJ social_JJ and_CC clinical_JJ characteristics_NNS [_NN 23_CD –_NN 26_CD ]_NN ._. Of_IN
        particular_JJ note_NN are_VBP the_DT lower_JJR rates_NNS of_IN statin_NN use_NN in_IN at-risk_JJ younger_JJR patients_NNS ,_, females_NNS ,_,
        African-_NNP Americans_NNPS ,_, and_CC patients_NNS cared_VBD for_IN by_IN non-cardiologists_JJ ._. These_DT findings_NNS may_MD be_VB
        useful_JJ for_IN guiding_VBG targeted_VBN interventions_NNS that_WDT aim_NN to_TO bring_VB physician_NN practice_NN into_IN
        agreement_NN with_IN published_VBN guidelines_NNS for_IN cardiovascular_JJ risk_NN reduction_NN ._.
        Our_PRP$ findings_NNS must_MD be_VB interpreted_VBN in_IN the_DT context_NN of_IN data_NNS limitations_NNS ._. Although_IN both_DT NAMCS_NNP
        and_CC NHAMCS_NNP are_VBP designed_VBN to_TO produce_VB nationally_RB representative_NN estimates_NNS ,_, these_DT estimates_NNS are_VBP
        not_RB linked_VBN to_TO individuals_NNS but_CC to_TO patient_NN visits_NNS ._. As_IN a_DT result_NN ,_, reported_VBD statin_NN use_NN may_MD
        overestimate_NN the_DT actual_JJ administration_NN because_IN patients_NNS prescribed_VBN drug_NN therapy_NN likely_JJ make_NN
        more_JJR visits_NNS because_IN of_IN greater_JJR disease_NN severity_NN and_CC /_NN or_CC the_DT need_NN of_IN frequent_JJ follow-ups_JJ ._.
        Also_RB ,_, we_PRP are_VBP missing_VBG people_NNS with_IN risk_NN factors_NNS who_WP have_VBP not_RB been_VBN seen_VBN by_IN a_DT physician_NN or_CC
        whose_WP$ risk_NN factors_NNS failed_VBD to_TO be_VB recorded_VBN ._. On_IN the_DT other_JJ hand_NN ,_, underestimation_NN is_VBZ also_RB
        possible_JJ ,_, for_IN example_NN ,_, because_IN of_IN physicians_NNS '_POS lack_NN of_IN awareness_NN or_CC incomplete_JJ reporting_NN of_IN
        patient_NN medication_NN uses_NNS ._. However_RB ,_, the_DT failure_NN to_TO inquire_NN or_CC report_VB an_DT important_JJ agent_NN such_JJ
        as_IN a_DT statin_NN may_MD be_VB a_DT clinical_JJ oversight_NN in_IN itself_PRP and_CC contribute_VB to_TO therapeutic_JJ gaps_NNS ._. The_DT
        degree_NN of_IN inaccuracy_NN in_IN our_PRP$ estimates_NNS is_VBZ perhaps_RB small_JJ ,_, however_RB ,_, as_IN suggested_VBN by_IN the_DT
        comparability_NN of_IN the_DT current_JJ results_NNS to_TO previous_JJ reports_NNS ._.
        Lack_NN of_IN detailed_JJ clinical_JJ data_NNS prohibits_VBZ accurate_JJ risk_NN assessment_NN based_VBN on_IN Framingham_NNP
        risk_NN scoring_VBG ._. While_IN the_DT risk_NN factor_NN counting_VBG algorithm_NN that_IN we_PRP used_VBD may_MD simulate_VBP practical_JJ
        risk_NN estimation_NN by_IN many_JJ physicians_NNS ,_, it_PRP precludes_VBZ the_DT assessment_NN of_IN appropriateness_NN of_IN
        statin_NN use_NN in_IN relation_NN to_TO the_DT latest_JJS lipid-lowering_JJ guidelines_NNS ._. This_DT creates_VBZ difficulty_NN
        interpreting_VBG the_DT rate_NN of_IN statin_NN use_NN observed_VBD for_IN the_DT moderate-risk_JJ group_NN ._. In_IN particular_JJ ,_,
        adequate_JJ information_NN is_VBZ not_RB available_JJ to_TO differentiate_VB varying_VBG levels_NNS of_IN absolute_JJ risk_NN
        among_IN the_DT moderate-risk_JJ group_NN ._. We_PRP likely_RB misclassified_VBN some_DT patients_NNS as_IN moderate_JJ risk_NN when_WRB
        they_PRP may_MD have_VB actually_RB been_VBN high_JJ risk_NN despite_IN the_DT absence_NN of_IN CHD_NNP or_CC CHD_NNP equivalents_NNS ._. On_IN the_DT
        other_JJ hand_NN ,_, indications_NNS for_IN statins_NNS might_MD be_VB marginal_JJ for_IN some_DT young_JJ patients_NNS with_IN modestly_RB
        elevated_VBD risk_NN factors_NNS ._. A_DT final_JJ caveat_NN is_VBZ that_IN neither_DT NAMCS_NNP nor_CC NHAMCS_NNP captures_NNS patient_NN
        compliance_NN or_CC outcomes_NNS ,_, although_IN these_DT are_VBP perhaps_RB separate_JJ issues_NNS from_IN physician_NN adherence_NN
        to_TO evidence-based_JJ medicine_NN ._.
        Despite_IN the_DT acknowledged_VBN limitations_NNS ,_, NAMCS_NNP and_CC NHAMCS_NNP cover_VBP a_DT longer_RBR consecutive_JJ time_NN
        span_NN and_CC provide_VB more_RBR complete_JJ information_NN about_IN disease-specific_JJ physician_NN activities_NNS than_IN
        many_JJ other_JJ national_JJ data_NNS bases_NNS ,_, e_SYM ._. g_SYM ._. ,_, the_DT Medical_NNP Expenditures_NNPS Panel_NNP Survey_NNP ,_, the_DT National_NNP
        Health_NNP Assessment_NNP Nutrition_NNP Examination_NNP Survey_NNP ,_, and_CC the_DT National_NNP Health_NNP Interview_NNP
        Survey_NNP ._.
        In_IN conclusion_NN ,_, persistent_JJ gaps_NNS in_IN statin_NN therapy_NN suggest_VBP a_DT continued_VBN need_NN for_IN improved_VBN
        CHD_NNP risk_NN stratification_NN of_IN all_DT patients_NNS ,_, and_CC treatment_NN with_IN statins_NNS when_WRB indicated_VBD ._.
        Information_NN technology_NN and_CC broader_JJR national_JJ policy_NN around_IN quality_NN measurement_NN and_CC reporting_VBG
        are_VBP just_RB two_CD potential_JJ strategies_NNS that_WDT could_MD be_VB used_VBN to_TO improve_VB current_JJ practice_NN ._.
        Patient-centered_NNP interventions_NNS should_MD strengthen_VB patient_NN education_NN and_CC improve_VB patient_NN
        access_NN to_TO different_JJ treatment_NN options_NNS ._. Interventions_NNP should_MD be_VB targeted_VBN to_TO at-risk_JJ patients_NNS
        whose_WP$ drug_NN regimens_NNS need_VBP to_TO be_VB reassessed_JJ and_CC to_TO physicians_NNS ,_, particularly_RB
        non-cardiologists_JJ ,_, whose_WP$ practices_NNS need_VBP be_VB improved_VBN ._. Guidelines_NNS for_IN cardiovascular_JJ risk_NN
        reduction_NN treatment_NN and_CC determination_NN of_IN the_DT specific_JJ patients_NNS who_WP can_MD benefit_VB from_IN statin_NN
        therapy_NN will_MD continue_VB to_TO evolve_VB ._. Indications_NNP for_IN use_NN in_IN primary_JJ CHD_NNP prevention_NN are_VBP likely_JJ
        to_TO expand_VB for_IN statins_NNS ._. Given_VBN the_DT observed_VBN practice_NN shortfalls_NNS ,_, drug_NN therapy_NN in_IN
        moderate-risk_JJ patients_NNS remains_VBZ an_DT important_JJ priority_NN for_IN improvement_NN ._.
      
    
  
